Primary Objectives. The primary objectives of this study is to demonstrate safety, tolerability and activity of cabozantinib and lanreotide association in patients with well differentiated GEP, Thoracic and unknown primary NET To evaluate safety and tolerability of cabozantinib plus lanreotide To evaluate safety and tolerability of cabozantinib plus lanreotide. To evaluate the activity of cabozantinib and lanreotide combination in terms of objective response rate according to the RECIST 1.1 criteria.
